Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sales Growth Leaves Analysts Bullish On Cubist’s Cubicin

This article was originally published in The Pink Sheet Daily

Executive Summary

Injectable antibiotic continues to pry away market share from generic vancomycin.

You may also be interested in...



Cubist Gets Entereg And A Late-Stage Compound With Adolor Buy

The deal includes a contingent payment right tagged to Phase III-ready constipation drug ADL5945 that will provide extra consideration for Adolor shareholders if the drug reaches its upside potential.

Cubist Gets Entereg And A Late-Stage Compound With Adolor Buy

The deal includes a contingent payment right tagged to Phase III-ready constipation drug ADL5945 that will provide extra consideration for Adolor shareholders if the drug reaches its upside potential.

Deals Of The Week: UCB/Wilex, J&J/Vanderbilt, Alnylam/Cubist ...

Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.

Related Content

Topics

UsernamePublicRestriction

Register

OM006051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel